Cetera Investment Advisers grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 5.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,789 shares of the medical research company’s stock after purchasing an additional 5,593 shares during the period. Cetera Investment Advisers’ holdings in Thermo Fisher Scientific were worth $52,982,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Howard Capital Management Inc. boosted its position in Thermo Fisher Scientific by 0.5% during the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock worth $1,791,000 after purchasing an additional 16 shares during the period. Petros Family Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 3.9% in the fourth quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company’s stock worth $264,000 after buying an additional 17 shares during the period. Salomon & Ludwin LLC lifted its position in Thermo Fisher Scientific by 1.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock worth $669,000 after acquiring an additional 17 shares in the last quarter. Pallas Capital Advisors LLC grew its position in Thermo Fisher Scientific by 1.5% in the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock valued at $728,000 after acquiring an additional 18 shares in the last quarter. Finally, Red Door Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 0.8% during the fourth quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company’s stock worth $1,250,000 after purchasing an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.
Trending Headlines about Thermo Fisher Scientific
Here are the key news stories impacting Thermo Fisher Scientific this week:
- Positive Sentiment: Thermo Fisher beat Q2 expectations on both earnings and revenue, reporting $6.03 in adjusted EPS versus $5.71 expected and $11.99 billion in revenue versus $11.71 billion expected, with organic revenue up 5% year over year. Reuters article
- Positive Sentiment: The company raised its FY 2026 guidance, signaling management’s confidence that customer demand recovery should continue and that the stronger quarter was not a one-off. Business Wire article
- Positive Sentiment: Analysts pointed to broad-based improvement in life sciences and biopharma activity, plus price target upgrades, as additional support for the stock’s rally. Yahoo Finance article
- Neutral Sentiment: Thermo Fisher also launched InstaFlux for food microbiology labs, a product announcement that may help long-term workflow adoption but is not likely the main driver of the stock move today. Business Wire article
- Neutral Sentiment: One analyst note suggested the strong quarter may not materially change the second-half outlook, indicating some caution after the earnings beat. Yahoo Finance article
Insider Buying and Selling at Thermo Fisher Scientific
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Royal Bank Of Canada boosted their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday. Morgan Stanley reissued an “overweight” rating and issued a $650.00 price target on shares of Thermo Fisher Scientific in a report on Friday. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $613.05.
Thermo Fisher Scientific Stock Performance
Shares of TMO opened at $567.34 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a market capitalization of $210.83 billion, a price-to-earnings ratio of 30.52, a PEG ratio of 2.51 and a beta of 0.87. The stock has a 50 day moving average of $494.01 and a 200 day moving average of $513.46. The company has a current ratio of 1.55, a quick ratio of 1.15 and a debt-to-equity ratio of 0.74.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.08 earnings per share for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.34%.
About Thermo Fisher Scientific
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
